Review

# Technological Advances in Detection and Diagnosis of Cancer

 Vadlapudi Varahalarao

**Diabetomics Medical Private Limited, Hyderabad, India**

**Abstract**

Cancer is a major global health problem and leading cause of death globally. Recent advances in approaches and instrumentation in diagnosis of cancer become accurate, precise and save human lives. Early-stage detection of cancer is essential for the treatment and disease management. There have been several new advancements within radiation oncology in terms of utilizing Positron emission tomography (PET). The most widely used imaging method present for the diagnosis of cancers is the PET and F-FDG-PET/CT. Fluorescence in situ hybridization (FISH) procedure is possible to recognize tumor-specific abnormality. Enzyme-linked immunosorbent assay (ELISA) is the most frequently used technique amongst immunoassays for cancer detection and diagnosis. In the coming years, it is expected for molecular diagnostics metabolomics will play a crucial role in cancer detection. Scientists developed affordable, accurate, and simpler ELISA based detection for various cancers. Protein biomarkers for cancer detection typically emerge from the cancer cells. Molecular based techniques Polymerase chain Reaction (PCR), RNA-based assays, Nanotechnology (NT) based, Artificial intelligence (AI) and Bioinformatics based are emerging as more accurate and speedy techniques for early detection of cancer.

**Keywords:** Artificial intelligence, bioinformatics, cancer, Polymerase Chain Reaction (PCR)

*Cite This Article: Varahalarao V. Technological Advances in Detection and Diagnosis of Cancer. EJMA 2024;4(2):74–79.*

Cancer is a major public health problem and leading cause of death globally,[1] causing one in six deaths. The major challenge is to accurately diagnose it at an early stage. Recent advances in approaches and instrumentation at molecular level the diagnosis of cancer become accurate, precise and save human lives. Human disease is also considered as the cause of the interaction between genetic and environmental factors. Challenges facing the early detection research fall into mainly five broad categories 1. Understanding the biology of early cancer 2. Determining risk of developing cancer 3. Finding and validating cancer detection biomarkers 4. Developing accurate technologies for early detection 5. Evaluating early detection approaches. In the coming years, it is expected for molecular diagnostics like bioinformatics and metabolomics will play a crucial role in cancer detection,[2,3] one approach for lung cancer detection traditionally followed is Tissue-based histopathological.[4] Molecular diagnostics rely heavily on the detection and quantification of cancer biomarkers. For diagnosing a cancer need potential biomarkers "a biological molecule found in tissues, other body fluids, blood (Circulating tumor DNA, circulating tumor cells, proteins, exosomes, and cancer metabolites) that provides information about a condition or disease and abnormal or normal process of cancer. There is an urgent need to find new signatures or biomarkers for early detection and prognosis. Oral cancers are the sixth most frequent cancer with a high mortality rate than Cervical cancer. Advances in Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.[5] Early diagnosis of cancers and it plays a crucial role in the subsequent treatments and due to the recently new biomarker are found by DNAzyme-assisted aptasensors.[6]

## Positron Emission Tomography (PET) Based Detection

Early detection and staging of recurrence are also essential for optimal therapeutic management. The most widely used imaging method present for the diagnosis of cancers is the PET and F-FDG-PET/CT is the current state-of-the-art diagnostic imaging and has shown accurate staging of nonsmall cell lung cancers, anatomical and functional information of nonoperative head and neck cancer[7,8] and performs better for invasive ductal carcinoma and of staging invasive lobular carcinomas.[9] There have been several new advancements within radiation oncology in terms of utilizing PET scans in conjunction with certain tracers in order to identify and stage several types of cancer. Other variant FAPI-PET used to detect both the presence and activity of lung fibrogenesis.[10] Detection of Synchronous Esophageal Cancer (SEC) in Pharyngeal Cancer was achieved with high sensitivity.[11] With the help of PET found skeletal metastases in patients with prostate cancer[12,13] or breast cancer,[14] in human papillomavirus-associated oropharyngeal cancer,[15] pancreatic cancer,[16] gastrointestinal stromal tumors.[17]

## Magnetic Resonance Spectroscopy (MRS)

MRS is a widely used form of imaging techniques used for the diagnosis of cancer. MRS detects metabolic changes in tumors such as total choline (Cho) levels and ratios with other metabolites in detection of cancer. MRS has a clinical role in grading gliomas along with other imaging features like necrosis enhancement and haemorrhage it can be useful to finding low grade vs glioma high grade glioma. MRS having own limitations like considerable overlap between the spectroscopic appearance of different pathology and lack of definitive imaging findings.[18] Research and Development is currently underway to increase the clinical usefulness of MRS in brain tumor diagnosis and treatment.

## Fluorescence in situ Hybridization (FISH) and Chromogenic in situ Hybridization (CISH) Based Detection

FISH technique developed in 1980s. FISH procedure is possible to recognize tumor-specific abnormality. By comparing the hybridization pattern of cancer cells with the normal cells comparative genomic hybridization (CGH), can identify chromosome losses and gains in tumor cells. Modern concept of FISH technique present microfluidic platforms which are dedicated to the analysis of circulating tumor cells (CTCs).[19] FISH analysis used in Solid Tumors diagnostics in Lung, breast cancer, soft tissue sarcomas, Ovarian Cancer.[20,21]

## Enzyme-Linked Immunosorbent Assay (ELISA) Based Detection

ELISA, is the most frequently used technique amongst immunoassays. Accurate, rapid, and simple detection methods are required to facilitate early diagnosis of cancer.[22] Cervical cancer is the third most common cancer in women. Scientists developed affordable, accurate, and simpler ELISA based detection for Cervical cancer.[23] microchip ELISA that detects HE4, an ovarian cancer biomarker, from urine using a cell phone integrated with a mobile application for imaging and data analysis.[24] ELISA can used for detection of Salivary interleukin-6 in oral cancer and precancer.[25]

## Rapid Point-of-Care (POC) Detection

Early-stage detection of cancer is essential for the treatment and disease management. In molecular diagnosis, extracellular vesicles play significant role in biomarker discovery of cancer. POC (electrochemical, surface plasma resonance (SPR), Microfluidic systems) devices are simple to use, affordable, quick, and robust to analyse clinical samples at home or at medical diagnostics centre.[26] Protein biomarkers for cancer detection typically emerge from the cancer cells. Due to the poor stability of protein biomarkers of cancer the test should consider the paraments like sensitivity, specificity, and accuracy.[27]

## PCR Based Detection

Cancer diagnosis at the preliminary stage is challenging, entailing sophisticated diagnostic methods. The emergence of practical applications of molecular biology techniques (PCR and RNA-based assays) are largely attributed for molecular analysis of cancer. Polymerase chain reaction (PCR) require simple instrumentation and infrastructure in clinical DNA testing relatively.[28] Although ELISA is the method of choice in clinical practice for detecting cancer biomarkers in serum/urine samples. iPCR technique is 1000-fold more sensitive than the conventional ELISA and can detect even a single antigen molecule.[29] New method was developed for detecting T790 M point mutations in lung cancer biopsies using PCR-LFA.[30] Colorectal cancer (CRC) is the fourth leading cause of the cancer death worldwide.[31] Many methylation markers associated with colorectal cancer have been reported.[32] and Early detection of Circulating tumor DNA-based precancerous colorectal lesions using QClamp XNA-mediated real-time PCR[33] and multiplex RT-PCR assay for colorectal cancer detection.[34] Develop a multiplex PCR-based method for detection of circulating tumor cells in peripheral blood of lung cancer (LC).[35]

## Artificial Intelligence (AI) Based Detection

Early cancer diagnosis and artificial intelligence (AI) are rapidly evolving fields with important areas of convergence

and detection was well established.[36] Machine learning (ML), a subdivision of AI. AI comes with several challenges, like data security. Approaches are emerging to improve data security and reduce the risks associated with transferring data across multiple institutions.[37] Deep learning (DL) is a subgroup of ML (Machine learning). AI and its deep learning (DL) have also pervaded the field of breast cancer detection using mammography.[38] CRC, which represents the third most diagnosed malignancy in both men and women.[39] AI algorithms has permeated the medical field with great success for diagnosis of colorectal cancer (CRC). AI has been found to be useful to physicians in the field of image recognition. Gastric cancer is the fifth most common form of malignant tumor and the third leading cause of cancer-related death worldwide.[40] Japanese endoscopists have produced the world's first convolutional neural networks (CNN)-based AI system for detecting gastric and esophageal cancers.[41,42] breast cancer imaging, AI can detect mammographic abnormalities with comparable accuracy.[43,44] Lung cancer is one of the most common malignant tumors with the fastest increase in morbidity and mortality and the diagnosis mainly relies on tissue biopsy and computed tomography (CT). AI system can detect malignant pulmonary nodules based on chest CT images[45] and in CT film analysis it is assisting doctors in improving lung cancer screening accuracy. AI system can detect tumor detection but also can be used in staging of lung cancer.[46] AI can improve the efficiency of the cytopathological diagnosis of lung cancer. AI could also be used detecting mutant genes in lung cancer. Data analysis methodologies like AI (ML) tools are also accelerating progress.[47,48]

## Nanotechnology (NT) Based Detection

Advances in nanotechnology and medical science have spurred the development of engineered nanoparticles (NPs) and nanomaterials with particular focus on their applications in molecular diagnosis. Nanomaterials and nanotechnologies will greatly enhance the throughput and sensitivity of the identification and screening of potential biomarkers. NPs such as polymeric carbon nanotubes (CNTs), nanoparticles (nanogels, nanofibers, liposomes), calcium nanoparticles (CaNPs), metallic nanoparticles such as gold NP (GNPs), sliver NP (AgNP), graphene, and quantum dots (QDs) have revolutionized cancer diagnostics and defection. QDs (Quantom dots) are a type of semiconductor NPs that can emit fluorescence signals under ultraviolet light (UV) irradiation with a high quantum yield. Potential applications of QDs in molecular diagnostics can be Cancer. In Ovarian cancer biomarker CA125, human epididymis protein 4 (HE4), mucin 1 (MUC1), and prostate identified using NT.[49] Graphene is good at amplifying detection signals, and its derivatives play an important role in the early

diagnosis and cancer Novel Graphene-Based Multifunctional Nanomaterials are developed for detection.[50]

## Bioinformatics (BI) Based Detection

BI is one of the newest fields of biological research its use of mathematical, statistical, and computational methods for the processing and analysis of biological data. Currently, there is a growing need to convert biological data into knowledge through a bioinformatics approach.[51] Diagnosis and detection of pancreatic cancer early is the key to successful clinical management and improve the patient outcome. In recent years, with the rapid development of bioinformatics, an increasing amount of microarray and sequencing data have provided a convenient to elucidate molecular mechanisms for the cancer diagnosis. [52] analysed prognostic value of PITX1 gene in breast cancer by using BI tools Oncomine, Bc-GenExMiner v4.3, PrognoScan and UCSC Xena. Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive cancers on globe.[53] BI strengthened greatly the research and ITS application of liquid biomarkers. For the studying of liquid biopsies uses alignment of sequences.[54] BI facing another challenge for tumor circulome is to differentiate tumor mutations from background somatic mutations. Metastasis is a serious event in the clinic, leading to most deaths of melanoma patients This study provided a deeper understanding of the molecular mechanisms of melanoma metastasis.[55] In the results, cell mitosis and malignant proliferation were activated, whereas the interaction with the extracellular environment was suppressed during the metastatic process One of study may contribute to the more profound elucidation of mechanisms of melanoma metastasis.[56] Novel and high-performance genomic technologies allow detection of signals from cancers in blood, giving rise to a new paradigm of multi-cancer early detection (MCED). MCED tests analyze genomic features of circulating cfDNA and distinguish these from background genomic signals. New multi-cancer early detection (MCED) tests-using a single blood sample-have been developed based on circulating cell-free DNA (cfDNA) or other analytes. Doctors and Healthcare providers need to consider how to implement MCED testing for large numbers of cancer patients.[57]

## Volatile Organic Compound (VOC) Analysis

The detection and quantification of volatile organic compounds (VOCs) within exhaled breath used for diagnosis of cancer.[58] Most pancreatic cancer patients are diagnosed at an advanced stage Field asymmetric waveform ion mobility spectrometry (FAIMS) was used for VOC and evaluated FAIMS to discriminate between pancreatic cancer and healthy controls in a urine sample.[59] VOCs used as new biomarkers for colorectal cancer detection.[60] Lung cancer

is the world's deadliest cancer, but early diagnosis helps to improve the cure rate and thus reduce the mortality rate and based on LC-MS/MS VOCs Lung Cancer was detected. Studies suggested VOC signatures emanating from urine can be detected in patients with CRC using ion mobility spectroscopy technology (FAIMS).[61,62] Studied Hepatocellular Carcinoma was detected using VOC. No reliable diagnostic methods are available for gallbladder cancer (GBC) but assessed whether VOCs could be used as a diagnostic tool for GBC.[63]

## Conclusions with Future Perspectives

Now a days proactive approach to detecting cancer at an early stage can make treatments more effective, with fewer side effects and improve long-term survival of human race. In this review, we have explained various types of systems for detection and diagnostics of cancer in detailed using novel and emerging techniques. AI play a vital role in cancer detection. AI comes with several challenges, including algorithmic fairness, data bias, ethical considerations, and data security. Despite the challenges mentioned, the implications of AI for early cancer diagnosis are highly promising, and this field is likely to grow very rapidly in the coming years.

**Disclosures**

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.

## References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249.

2. Cheung PK, Ma MH, Tse HF, Yeung KF, Tsang HF, Chu MKM, et al. The applications of metabolomics in the molecular diagnostics of cancer. Expert Rev Mol Diagn 2019;19(9):785–793.

3. Ryska A, Dziadziuszko R, Olszewski W, Berzinec P, Öz B, Gottfried M, et al. Molecular diagnostics of lung cancer. Magy Onkol 2015;59(3):259–266. Hungarian.

4. Mairinger T. Histology, cytology and molecular diagnostics of lung cancer. Pathologe 2019;40(6):649–661. German.

5. Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, et al. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis 2020;11(5):346.

6. Kamali H, Golmohammadzadeh S, Zare H, Nosrati R, Fereidouni M, Safarpour H. The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors. J Nanobiotechnology 2022;20(1):438.

7. Wegen S, van Heek L, Linde P, Claus K, Akuamoa-Boateng D, Baues C, et al. Head-to-head comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for radiotherapy planning in head and neck cancer. Mol Imaging Biol 2022;24(6):986–994.

8. Zanoni L, Bezzi D, Nanni C, Paccagnella A, Farina A, Broccoli A, et al. PET/CT in non-hodgkin lymphoma: A update. Semin Nucl Med 2023;53(3):320–351.

9. Groheux D. FDG-PET/CT for Primary staging and detection of recurrence of breast cancer. Semin Nucl Med 2022;52(5):508–519.

10. Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, et al. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging 2022;49(11):3705–3716.

11. Tsuzuki H, Suzuki H, Tamaki T, Sone M, Hanai N. Detection ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for clinical T classification of synchronous esophageal cancer in pharyngeal cancer. Anticancer Res 2022;42(9):4597–4602.

12. Rosar F, Khreish F, Marlowe RJ, Schaefer-Schuler A, Burgard C, Maus S, et al. Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2023;50(9):2899–2909.

13. Zattoni F, Artioli P, Burei M, Chiaravalloti A, Chierichetti F, Donner D, et al. Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer. Q J Nucl Med Mol Imaging 2023;67(2):167–173.

14. Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, et al. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): A multicentre, phase 3 trial. Lancet Oncol 2022;23(12):1499–1507.

15. Liu ZY, Khoo D, Hartel G, Punyadeera C, Vasani S. Post-treatment 18F-fludeoxyglucose-positron emission tomography in human papillomavirus-associated oropharyngeal cancer. Head Neck 2023;45(8):2000–2008.

16. Kuroda Y, Oda T, Shimomura O, Louphrasitthiphol P, Mathis BJ, Tateno H, et al. Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. Cancer Sci 2023;114(8):3364–3373.

17. Wu C, Zhang X, Zeng Y, Wu R, Ding L, Xia Y, et al. [18F]FAPI-42 PET/CT versus [18F]FDG PET/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors. Eur J Nucl Med Mol Imaging 2022;50(1):194–204.

18. Weinberg BD, Kuruva M, Shim H, Mullins ME. Clinical applications of magnetic resonance spectroscopy in brain tumors: from diagnosis to treatment. Radiol Clin North Am 2021;59(3):349–362.

19. Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of Fluorescence In Situ Hybridization (FISH) in diagnosis and tailored therapies in solid tumors. Molecules 2020;25(8):1864.

20. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5(9):2892–2911.

21. Szeles A. Fluorescence in situ hybridization (FISH) in the molecular cytogenetics of cancer. Acta Microbiol Immunol Hung 2002;49(1):69–80.

22. Ito E, Iha K, Yoshimura T, Nakaishi K, Watabe S. Early diagnosis with ultrasensitive ELISA. Adv Clin Chem 2021;101:121–133.

23. Bose M, Sunder Singh S, Ganesharaja S, Chiwate AS, Hingmire SJ, Rajkumar T. Development and evaluation of p16 based double antibody sandwich ELISA for detection of cervical precancer and cancer. Asian Pac J Cancer Prev 2023;24(7):2337–2346.

24. Wang S, Akbas R, Demirci U. Microchip ELISA coupled with cell phone to detect ovarian cancer HE4 biomarker in urine. Methods Mol Biol 2015;1256:111–121.

25. Panneer Selvam N, Sadaksharam J. Salivary interleukin-6 in the detection of oral cancer and precancer. Asia Pac J Clin Oncol 2015;11(3):236–241.

26. Tothill IE. Biosensors for cancer markers diagnosis. Semin Cell Dev Biol 2009;20(1):55–62.

27. Thenrajan T, Alwarappan S, Wilson J. Molecular diagnosis and cancer prognosis-A concise review. Diagnostics (Basel) 2023;13(4):766.

28. Sokolenko AP, Imyanitov EN. Molecular diagnostics in clinical oncology. Front Mol Biosci 2018;5:76.

29. He X, Patfield SA. Immuno-PCR assay for sensitive detection of proteins in real time. Methods Mol Biol 2015;1318:139–148.

30. Dong N, Wang W, Lin S. Sensitive detection of T790M mutations in lung cancer biopsies using a PCR-based lateral flow assay. Anal Biochem 2022;637:114476.

31. Wong A, Ma BB. Personalizing therapy for colorectal cancer. Clin Gastroenterol Hepatol 2014;12(1):139–144.

32. Liu X, Wen J, Li C, Wang H, Wang J, Zou H. High-yield methylation markers for stool-based detection of colorectal cancer. Dig Dis Sci 2020;65(6):1710–1719.

33. Chen S, Wang Y, Wang K, Zhang L, Zhang X. Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR. Pharmazie. 2021;76(12):606–610.

34. Tsouma A, Aggeli C, Lembessis P, Zografos GN, Korkolis DP, Pectasides D, et al. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol 2010;16(47):5965–5974.

35. Katseli A, Maragos H, Nezos A, Syrigos K, Koutsilieris M. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.

Clin Lung Cancer 2013;14(5):513–520.

36. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395–409.

37. Hunter B, Hindocha S, Lee RW. The role of artificial ıntelligence in early cancer diagnosis. Cancers (Basel) 2022;14(6):1524.

38. Sechopoulos I, Teuwen J, Mann R. Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art. Semin Cancer Biol 2021;72:214–225.

39. Mitsala A, Tsalikidis C, Pitiakoudis M, Simopoulos C, Tsaroucha AK. Artificial intelligence in colorectal cancer screening, diagnosis and treatment. A new era. Curr Oncol 2021;28(3):1581–1607.

40. Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017;20(2):217–225.

41. Hirasawa T, Aoyama K, Tanimoto T, Ishihara S, Shichijo S, Ozawa T, et al. Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. Gastric Cancer 2018;21(4):653–660.

42. Suzuki H, Yoshitaka T, Yoshio T, Tada T. Artificial intelligence for cancer detection of the upper gastrointestinal tract. Dig Endosc 2021;33(2):254–262.

43. Schaffter T, Buist DSM, Lee CI, Nikulin Y, Ribli D, Guan Y, et al. Evaluation of combined artificial intelligence and radiologist assessment to interpret screening mammograms. JAMA Netw Open 2020;3(3):e200265.

44. Rodriguez-Ruiz A, Lång K, Gubern-Merida A, Broeders M, Gennaro G, Clauser P, et al. Stand-alone artificial intelligence for breast cancer detection in mammography: Comparison with 101 radiologists. J Natl Cancer Inst 2019;111(9):916–922.

45. Ardila D, Kiraly AP, Bharadwaj S, Choi B, Reicher JJ, Peng L, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med 2019;25(6):954–961.

46. Kachouie NN, Shutaywi M, Christiani DC. Discriminant analysis of lung cancer using nonlinear clustering of copy numbers. Cancer Invest 2020;38(2):102–112.

47. McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature 2020;577(7788):89–94.

48. Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A. Artificial intelligence in digital pathology - New tools for diagnosis and precision oncology. Nat Rev Clin Oncol 2019;16(11):703–715.

49. Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ. Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci 2021;266:118914.

50. Gong W, Hu Z, Liang Y, Wang Y, Zheng R, Tan J, et al. Graphene-

based multifunctional nanomaterials in cancer detection and therapeutics. J Nanosci Nanotechnol 2018;18(8):5155–5170.

51. Fu Y, Ling Z, Arabnia H, Deng Y. Current trend and development in bioinformatics research. BMC Bioinformatics 2020;21(Suppl 9):538.

52. Wang Q, Zhao S, Gan L, Zhuang Z. Bioinformatics analysis of prognostic value of PITX1 gene in breast cancer. Biosci Rep 2020;40(9):BSR20202537.

53. Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer 2021;20(1):34.

54. Kivioja T, Vähärautio A, Karlsson K, Bonke M, Enge M, Linnarsson S, et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods 2011;9(1):72–74.

55. Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res 2014;27(1):19–36.

56. Xie R, Li B, Jia L, Li Y. Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci 2022;23(2):794.

57. Hackshaw A, Clarke CA, Hartman AR. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening. Cancer Cell 2022;40(2):109–113.

58. Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: A systematic review and meta-analysis. JAMA Oncol 2019;5(1):e182815.

59. Nissinen SI, Roine A, Hokkinen L, Karjalainen M, Venäläinen M, Helminen H, et al. Detection of pancreatic cancer by urine volatile organic compound analysis. Anticancer Res 2019;39(1):73–79.

60. Di Lena M, Porcelli F, Altomare DF. Volatile organic compounds as new biomarkers for colorectal cancer: A review. Colorectal Dis 2016;18(7):654–663.

61. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C, Westenbrink E, Hodges P, Thomas MG, et al. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS One 2014;9(9):e108750.

62. Bannaga AS, Tyagi H, Daulton E, Covington JA, Arasaradnam RP. Exploratory study using urinary volatile organic compounds for the detection of hepatocellular carcinoma. Molecules 2021;26(9):2447.

63. Zhang X, Gui X, Zhang Y, Liu Q, Zhao L, Gao J, et al. A panel of bile volatile organic compounds servers as a potential diagnostic biomarker for gallbladder cancer. Front Oncol 2022;12:858639.